Sickle Cell Gene Therapy Cost Effectiveness Draws Scrutiny At ASH

According to a study presented at the American Society of Hematology, based on existing gene therapy prices, equitable use of sickle cell disease gene therapy requires expanding into patients who are younger and have less severe disease.